Objectives: Very low birth weight (VLBW) infants are vulnerable to nosocomial infections and subsequent morbidity; including infections caused by Staphylococcus aureus: 85% of nosocomial S. aureus infections are caused by capsular polysaccharide (CPS) types 5 and 8. Altastapht is a polyclonal investigational human immunoglobulin G (IgG) with high levels of opsonizing S. aureus CPS types 5 and 8 IgG.
Introduction
Nosocomial blood stream infections are a leading cause of morbidity and mortality in the very low birth weight (VLBW) infant. [1] [2] [3] [4] In recent years, the incidence of antibiotic resistant Staphylococcus aureus infections are increasing and causing substantial burden in morbidity and cost of care. 3 Capsular polysaccharide (CPS) types 5 and 8 are responsible for 85% of S. aureus infections in older patients, 5 and protection from mortality with high levels of passive anti-staphylococcal immunoglobulin G (IgG) has been shown in animals. 6 The increased risk of S. aureus bacteremia in premature infants (the cumulative incidence is approximately 4%) 2 may be due, in part, to their immunocompromised status. Transplacental acquisition of maternally derived IgG is substantially reduced in premature infants. [7] [8] [9] Altastaph is a polyclonal investigational human IgG with high levels of opsonizing S. aureus CPS type 5 and 8 IgG.
In a pharmacokinetic (Phase 1) study Altastaph has been previously administered to a cohort of 29 VLBW infants at dosages of 10, 15, and 20 ml/kg infusions corresponding to 500, 750, and 1000 mg of Altastaph/kg, respectively (data on file, NABI Biopharmaceuticals). The primary objective of this current (Phase 2) study was to determine the safety of intravenous administration of 1000 mg of Altastaph/kg in VLBW infants. Secondary objectives included evaluating the pharmacokinetics and efficacy of Altastaph in preventing nosocomial S. aureus infections.
Materials and methods
This multicenter, randomized, double blinded, placebo controlled study was conducted in 20 neonatal intensive care units. Study protocol and consent forms were reviewed and approved by local institutional review boards. Prior written consent was obtained for eligible infants from parents or guardians.
Inclusion criteria
To be eligible for the study, neonates had to meet the following criteria: birth weight 500 to 1500 g, 3 to 7 days of age at the time of first infusion (study day 0), no known existing bacterial infections, direct bilirubin < 2.0 mg/dl, and serum creatinine <2.0 ml/dl. Neonates with severe congenital anomalies, cyanotic heart disease or those who received any intravenous immune globulins (IVIG) before the first infusion were excluded from the study. A total of 206 eligible infants, stratified by birth weight 500 to 1000 g and 1001 to 1500 g; meeting all other entry criteria were randomized equally to receive placebo (n ¼ 102) or Altastaph (104).
Investigational product
Altastaph is a solution of IgG containing a high concentration of antibody to type 5 and 8 CPS of S. aureus. The plasma is collected from healthy professional (screened) plasma donors immunized under an IND with StaphVAX s , a bivalent, S. aureus types 5 and 8 CPS-rEPA-conjugate vaccine, and IVIG prepared by an FDA approved manufacturing process, which includes a solventdetergent treatment step with tri-(n-butyl) phosphate and Triton X-100 to inactivate enveloped viruses such as hepatitis B, hepatitis C, and HIV, and a virus filtration step using a Planova 35 nm Virus Filter to reduce the level of some nonenveloped viruses such as hepatitis A. The active investigational product for this investigation was derived from one lot. Nabi follows all FDA and industry guidelines for collection and testing of plasma used for production of IVIG. All donors are screened through a Donor Health History Questionnaire (as required by FDA), which targets high risk behaviors. All plasma units are tested for HBsAg, anti-HIV, and anti-HCV by FDA approved screening methods (ELISA). All units are tested by NAT (nucleic acid testing -PCR) for HIV and HCV as required by FDA. In addition, and before fractionation, all units are tested by NAT for HBV and HAV as well as parvovirus; note these last three tests are not FDA required but are a Nabi requirement for manufacturing final product. The NAT testing is performed in pools of samples from individual units and if a pool should test positive, then individual testing is performed to determine positive units, which are then removed. Retesting of the new 'pool' is performed before clearance for inclusion in the bulk plasma pools that will undergo fractionation. During the process of fractionation and purification, several steps of viral inactivation also occur that are designed to inactivate any viral particles that might have escaped detection in the screening process.
The investigational product was infused as a 1000 mg/kg dose, which is equivalent by volume to 20 ml/kg and the same volume was infused in placebo (0.45% NaCl) recipients. Each infusion was administered over approximately 3 to 5 h. The two infusions were given 14 days apart (approximately postnatal days 5 and 19). The placebo (0.45% NaCl) was prepared in accordance to standard practice at the site. We used 0.45% NaCl as the placebo, because a prior IVIG trial using 5% albumin had increased rates of NEC in the placebo arm as compared to baseline rates. 4 The interval, dosage, and subsequent target levels of CPS 5 and 8 were selected based on the levels observed in the Phase 1 study and anticipated elimination of IVIG in premature infants. The sites were to maintain total daily fluid and glucose administration per local standard of care; investigators were encouraged to provide the same amount of total fluids on the day of infusion as they had on the day before infusion. Patients were followed for 28 days after second infusion or until discharge from the nursery.
Immunoglobulin G assay Plasma samples were assayed for S. aureus types 5 and 8 CPS IgG using a validated ELISA method (Nabi Biopharmaceuticals, Rockville, MD, USA). Overall precision of the method using quality control samples, as measured by relative standard deviation, was less than or equal to 10%. Total IgG levels were determined using a commercial radial immunodiffusion assay. Geometric mean (GM) IgG levels were derived from samples obtained approximately on study days 0, 1, 14, 15, 21, and 28. These represented samples 1 day before and after first infusion, 1 day before and after second infusion, and 1 and 2 weeks after second infusion, respectively.
Safety measures
Safety was assessed from the frequency, intensity, and relationship to study drug of adverse events (AE) throughout the study. These included the results of clinical laboratory tests (CBC, serum chemistry, bilirubin, and liver enzymes), and clinical assessment while on study. Prior and concomitant medications were recorded for each patient. Adverse events were standardized and recorded per protocol.
10-12
Invasive infections A limited efficacy analysis was a secondary end point; outcome for each patient was categorized by site of infection and organism. Sterile body fluids were defined as blood, cerebrospinal fluid, peritoneal fluid, and urine by in/out catheterization or suprapubic bladder aspiration. Bacterial isolates were characterized as true pathogens (e.g., S. aureus, Serratia, Pseudomonas, Enterobacter, etc.), skin contaminants (e.g., Propionibacteria), and coagulase negative staphylococcal (CoNS) infections. Therefore, invasive S. aureus infection was defined as positive culture from a normally sterile body fluid.
Coagulase negative staphylococcal infections were further categorized as possible infections (one positive culture from sterile body fluid or positive cultures separated by >5 days), probable infections (two positive cultures in p5 days), or definitive infection (two positive cultures on the same day or three or more positive cultures in p5 days). 13, 14 It is acknowledged that the definitions for CoNS are imperfect and uncertain, and these definitions would influence the reported cumulative incidence of CoNS infection. CRP levels to assist in the classification of CoNS infections were not obtained. Aerobic blood cultures obtained from infants were evaluated to exclude infection before study entry. Cultures (and number of cultures) were obtained as clinically indicated (local investigator discretion) throughout the study.
Analysis
Data from all patients who received a dose of Altastaph or placebo were analyzed for pharmacokinetics, safety, and efficacy. The study was not powered for efficacy. Sample size calculations were based on the absolute differences in the width of 95% confidence intervals (CI) calculated by exact methods for AE. A sample size of 100 in each arm was estimated to be able to provide an absolute difference in 95% CI of 9 to 13%: for examplr, if there were five deaths in the placebo arm, then the 95% CI was expected to be (0.02, 0.11), and if there were 10 cases of IVH in the study product arm, then the 95% CI was expected to be (0.05, 0.18). Two-tailed CI calculated by exact methods are presented for AE, and all CI presented are 95%.
Results
In total, 206 VLBW infants (Altastaph group n ¼ 104 and placebo group n ¼ 102) were enrolled from 18/20 centers. The gender and racial demographics of the two groups were similar: 56 and 57 male infants were enrolled in the placebo and Altastaph groups, respectively; the proportions of white infants enrolled were 58 and 57% in the placebo and Altastaph groups, respectively, and the proportions of African-American infants were 31 and 33%. The median birth weight in the placebo group was 1055 g (standard deviation 268 g) and median birth weight in the Altastaph group was 1018 g (standard deviation 269 g). Each infant received at least one infusion, and 77% (158/206) received two infusions. Of the 48 infants who did not receive a second infusion most did not because they were discharged from the NICU, but 6/48 did not because they developed an AE and one family withdrew consent. The median age of all patients at first infusion was 5 days. The mean duration of study time was 33 days.
Pharmacokinetics
Immunoglobulin G levels for neonates born p1000 g birth weight were <5 mcg/ml for CPS 5 and 8 before the first infusion in both the placebo and Altastaph groups; Figures 1 and 2 depict CPS 5 (CPS 8, Figures available upon request) and these levels remained <5 mcg/ml for the entire study for the placebo group. In the Altastaph group, the GM for CPS type 5 was 402 mcg/ml on study day 1, 187 mcg/ml on day 14 (before second infusion), and 642 mcg/ml on day 15. The GM for CPS type 8 was 341 mcg/ml on day 1, 173 mcg/ml on day 14, and 542 mcg/ml on day 15. Geometric mean for both CPS 5 and 8 were X290 mcg/ml on days 21 and 28.
Immunoglobulin G levels for infants born 1001 to 1500 g were p5 mcg/ml for CPS types 5 and 8 before the first infusion in both groups, and were p5 mcg/ml for the duration of the study in the placebo group. In the Altastaph group, the GM levels for CPS 5 and 8 levels were consistently higher than those observed in neonates born p1000 g birth weight.
Safety Safety was comparable between groups and there was no statistically significant difference in the number of AEs or SAEs ( Table 1 ). We did not observe an unusually high rate of NEC or other key safety outcomes in this trial; nor did we observe a significantly higher rate of key safety parameters in one arm of the study compared to the other. There were three deaths in the placebo group (2.9%) and 4 (3.8%) in the Altastaph group. These deaths were felt to be unrelated to study infusions by the site investigator. In the Altastaph group deaths were attributed to Pseudomonas sepsis (2), S. aureus sepsis (1), and respiratory distress syndrome (1); and in the placebo group were related to Serratia sepsis(1), Pseudomonas sepsis (1), and gastric perforation (1). The infant who developed S. aureus (serotype 5) sepsis did so 7 days after first infusion (antibody levels 543 and 524 mcg/ml for serotypes 5 and 8, respectively), and died 6 days after developing bacteremia.
Invasive infections: 32 infants (16 in each group) developed an invasive infection with a definitive pathogen; three infants in each group developed bacteremia with S. aureus (Table 2) ; each isolate was either type 5 (n ¼ 3) or type 8 (n ¼ 3). In addition to the 32 infants presented in Table 2 , definitive CoNS infection occurred in three and one infants in the placebo and Altastaph group, respectively; probable CoNS infection occurred in two and three infants in the placebo and Altastaph group, respectively.
Discussion
Survival of VLBW neonates has improved dramatically, but invasive infections are a substantial cause of morbidity and mortality in this population. S. aureus bacteremia occurs in approximately 4% of VLBW infants. [1] [2] [3] [4] Although multiple interventions, to which these VLBW neonates are exposed in the nursery account for a portion of their predisposition to infection, multiple defects in opsonophagocytic host defense have also been identified. [7] [8] [9] Among these is hypogammaglobulinemia. Transplacental acquisition of IgG by the fetus is minimal before 32 weeks of gestation, and endogenous synthesis does not begin until 4 to 6 months after birth.
7-9 Preterm, VLBW neonates thus have a mean serum IgG levels of 400 to 500 mg/dl at birth (as contrasted with X700 mg/dl for the term infant). Furthermore, the levels of IgG decline to 100 to 200 mg/dl during the first 4 to 8 weeks of age in prematurely born infants. 1, 4, 9 The binding of IgG specific to CPS antigens are crucial to clearance of infections with Gram-positive bacteria. 15, 16 Thus, passive immunization of specific anti-CPS IgG may ameliorate the relative immunodeficiency of premature infants.
The prophylactic use of IVIG has been studied to determine if it might prevent nosocomial infections in VLBW neonates. These 4 revealed no overall benefit of IVIG administration. An interim analysis of the first 1218 infants showed that the IVIG group had a decreased relative risk of infection similar to that observed in the Baker trial. 1, 4 This effect, which disappeared during the second half of the trial, may have been mediated by one of the four lots of IVIG used in the study.
This observation led to speculation that functional IgG specific for important nosocomial pathogens may be critical for success in preventing infection in VLBW neonates. 4 As high levels of IgG, specific against S. aureus types 5 and 8 CPS are present in Altastaph; and these two serotypes are responsible for approximately 85% of S. aureus infections in neonates, we proposed to study the efficacy of Altastaph in this population.
Altastaph provided high levels of anti-S. aureus types 5 and 8 CPS IgG; GM levels were consistently >170 mcg/ml; however, the cumulative incidence of S. aureus bacteremia was nearly identical in the two groups (approximately 3%). The trial was not designed to detect a difference in the incidence of S. aureus, yet a comparison of the cumulative incidence of S. aureus in those infants who received placebo vs those who received Altastaph was a secondary end point. Given several prior trials of IVIG have reported moderate protection in the prevention of bacteremia, we considered several plausible explanations as to why the incidence was similar in the two groups. These included insufficient sample size to detect a low frequency occurrence of staphylococcal bacteremia, the infection control practices of the nurseries involved in the trial, and the efficacy of the product. The sample size of 200 infants in this study is consistent with the numbers enrolled in Phase II pilot trials. Given the B4% cumulative incidence of invasive S. aureus disease in this population, approximately 2000 infants would be necessary to detect a relative reduction of invasive disease. The equal incidence may therefore reflect distribution within a study that is simply too small to detect a difference. The nurseries enrolling in the trial may have affected the trial as follows. The cumulative incidence of S. aureus bacteremia was 3%, lower than previously reported; and while the low incidence reflects well of the infection control of the nurseries in this study, a low overall incidence of infection makes detecting a difference in prophylaxis studies less likely in a study not designed to detect such a difference.
Altastaph targets only S. aureus CPS 5 and 8, and therefore has no opsonic activity against the 10 to 15% of S. aureus that are neither type 5 or 8, nor against CoNS. Prophylaxis against a broader array of Staphylococci using targeted specific IgG technology is worthy of future investigation. A critical component of this study is that Altastaph is immunopreventive therapy specifically designed as prophylaxis of an organism that causes neonatal morbidity. The preliminary data suggest that 'immunoglobulin designing' is technologically feasible and that the challenge lies in finding the 'right' antibody mix to fit the disease.
From this study, we conclude that two infusions of an enhanced anti-CPS IgG preparation, 1000 mg Altastaph/kg were well tolerated in this population of VLBW infants. There were no differences in the frequency of AE in the treatment of placebo groups. The rates of invasive S aureus disease in the treatment and placebo groups were similar; however, the present study was not sufficiently powered to detect small differences. Using a larger sample, with greater pathogen protection (e.g., inclusion of CoNS specific IgG in the study drug) is scientifically plausible and worthy or future investigation.
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